Brief self-report measure of work-related cognitive limitations in breast cancer survivors

Journal of Cancer Survivorship

Volumn 7, Issue 2, 2013, Pages 262-273

  Ottati, Alicia ^a   Feuerstein, Michael ^b  

^a Uniformed Services University of the Health Sciences   (United States)

^b UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

Author keywords

Breast cancer survivor; Cognitive assessment; Employment; Patient reported outcomes

Indexed keywords

EID: 84876114497     PISSN: 19322259     EISSN: 19322267     Source Type: Journal    
DOI: 10.1007/s11764-013-0275-9     Document Type: Article

References (50)

1. SEER. SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations). Howlader, N., Noone, A. M., Krapcho, M., Neyman, N., Aminou, R., Altekruse, S. F., et al. (eds.). Bethesda, MD: National Cancer Institute; based on November 2011 SEER data submission, posted to the SEER website, 2012. Available from http://seer. cancer. gov/csr/1975_2009_pops09/. 2012.
2. Boykoff N, Moieni M, Subramanian SK. Confronting chemobrain: an in-depth look at survivors' reports of impact on work, social networks, and health care response. J Cancer Surviv. 2009; 3(4): 223-32.
3. Downie FP, Mar Fan HG, Houede-Tchen N, Yi Q, Tannock IF. Cognitive function, fatigue, and menopausal symptoms in breast cancer patients receiving adjuvant chemotherapy: evaluation with patient interview after formal assessment. Psychooncology. 2006; 15(10): 921-30.
4. Janelsins MC, Kohli S, Mohile SG, Usuki K, Ahles TA, Morrow GR. An update on cancer- and chemotherapy-related cognitive dysfunction: current status. Semin Oncol. 2011; 38(3): 431-8.
5. Shilling V, Jenkins V, Morris R, Deutsch G, Bloomfield D. The effects of adjuvant chemotherapy on cognition in women with breast cancer-preliminary results of an observational longitudinal study. Breast. 2005; 14(2): 142-50.
6. Breckenridge LM, Bruns GL, Todd BL, Feuerstein M. Cognitive limitations associated with tamoxifen and aromatase inhibitors in employed breast cancer survivors. Psychooncology. 2012; 21(1): 43-53.
7. Wefel JS, Lenzi R, Theriault RL, Davis RN, Meyers CA. The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma: results of a prospective, randomized, longitudinal trial. Cancer. 2004; 100(11): 2292-9.
8. Von Ah D, Habermann B, Carpenter JS, Schneider BL. Impact of perceived cognitive impairment in breast cancer survivors. Eur J Oncol Nurs. 2012: 1-6.
9. Munir F, Burrows J, Yarker J, Kalawsky K, Bains M. Women's perceptions of chemotherapy-induced cognitive side affects on work ability: a focus group study. J Clin Nurs. 2010; 19(9-10): 1362-70.
10. Wefel JS, Saleeba AK, Buzdar AU, Meyers CA. Acute and late onset cognitive dysfunction associated with chemotherapy in women with breast cancer. Cancer. 2010; 116(14): 3348-56.
11. Bender CM, Sereika SM, Berga SL, Vogel VG, Brufsky AM, Paraska KK, et al. Cognitive impairment associated with adjuvant therapy in breast cancer. Psychooncology. 2006; 15(5): 422-30.
12. Quesnel C, Savard J, Ivers H. Cognitive impairments associated with breast cancer treatments: results from a longitudinal study. Breast Cancer Res Treat. 2009; 116(1): 113-23.
13. Jenkins V, Shilling V, Deutsch G, Bloomfield D, Morris R, Allan S, et al. A 3-year prospective study of the effects of adjuvant treatments on cognition in women with early stage breast cancer. Br J Cancer. 2006; 94(6): 828-34.
14. Calvio L, Peugeot M, Bruns GL, Todd BL, Feuerstein M. Measures of cognitive function and work in occupationally active breast cancer survivors. J Occup Environ Med. 2010; 52(2): 219-27.
15. Hansen JA, Feuerstein M, Calvio LC, Olsen CH. Breast cancer survivors at work. J Occup Environ Med. 2008; 50(7): 777-84.
16. Hutchinson AD, Hosking JR, Kichenadasse G, Mattiske JK, Wilson C. Objective and subjective cognitive impairment following chemotherapy for cancer: A systematic review. Cancer Treat Rev. 2012; 38(7): 926-34.
17. Pullens MJ, De Vries J, Roukema JA. Subjective cognitive dysfunction in breast cancer patients: a systematic review. Psychooncology. 2010; 19(11): 1127-38.
18. Cheung YT, Tan EH, Chan A. An evaluation on the neuropsychological tests used in the assessment of postchemotherapy cognitive changes in breast cancer survivors. Support Care Cancer. 2012; 20(7): 1361-75.
19. Glisky EL. Changes in cognitive function in human aging. In: Riddle DR, editor. Brain Aging: Models, Methods, and Mechanisms. Boca Raton (FL): CRC Press; 2007. Chapter 1.
20. Wallace JC, Chen G. Development and validation of a work-specific measure of cognitive failure: implications for occupational safety. J Occup Organ Psychol. 2005; 78: 615-32.
21. Wagner L, Sweet J, Butt Z, Lai J, Cella D. Measuring patient self-reported cognitive function: development of the Functional Assessment of Cancer Therapy-Cognitive Function Instrument. J Support Oncol. 2009; 7: W32-9.
22. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993; 85(5): 365-76.
23. O'Hara C, Harrell M, Bellingrath E, Lisicia K. Cognitive symptom checklists: clinician's guide. Lutz (FL): Psychological Assessment Resources, Inc; 1993.
24. Feuerstein M, Hansen JA, Calvio LC, Johnson L, Ronquillo JG. Work productivity in brain tumor survivors. J Occup Environ Med. 2007; 49(7): 803-11.
25. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983; 67(6): 361-70.
26. Alexander S, Palmer C, Stone PC. Evaluation of screening instruments for depression and anxiety in breast cancer survivors. Breast Cancer Res Treat. 2010; 122(2): 573-8.
27. Lerner D, Amick BC III, Rogers WH, Malspeis S, Bungay K, Cynn D. The Work Limitations Questionnaire. Med Care. 2001; 39(1): 72-85.
28. Wagner L, Cella D, Doninger N. Chemotherapy-related cognitive deficits: a qualitative examination of patients and providers. Annals of Behavioral Medicine. 2003; 25(S56).
29. Jacobs SR, Jacobsen PB, Booth-Jones M, Wagner LI, Anasetti C. Evaluation of the functional assessment of cancer therapy cognitive scale with hematopoietic stem cell transplant patients. J Pain Symptom Manag. 2007; 33(1): 13-23.
30. Preacher KJ, Zhang G, Kim C, Mels G. Choosing the optimal number of factors in exploratory factor analysis: a model selection perspective. Multivariate Behavioral Research. in press.
31. Costello AB, Osborne JW. Best practices in exploratory factor analysis: four recommendations for getting the most from your analysis. Pract Assess Res Eval. 2005; 10(7): 1-9.
32. Kaiser H. A second generation little jiffy. Psychometrika. 1970; 35: 401-15.
33. Kaiser H. An index of factorial simplicity. Psychometrika. 1974; 39: 31-6.
34. Garson GD. Factor analysis (Statistical Associates "Blue Book" series). Kindle Edition ed: Statistical Associates Publishers; 2012.
35. Tabachnick BG, Fidell LS. Using multivariate statistics. 5th ed. Boston: Pearson/Allyn & Bacon; 2007.
36. Bartlett MS. A note on the multiplying factors for various chi square approximations. J R Stat Soc. 1954; 16 (Series B): 296-8.
37. Biglia N, Bounous VE, Malabaila A, Palmisano D, Torta DM, D'Alonzo M, et al. Objective and self-reported cognitive dysfunction in breast cancer women treated with chemotherapy: a prospective study. Eur J Cancer Care (Engl). 2012; 21(4): 485-92.
38. Shilling V, Jenkins V. Self-reported cognitive problems in women receiving adjuvant therapy for breast cancer. Eur J Oncol Nurs. 2007; 11(1): 6-15.
39. Munir F, Kalawsky K, Lawrence C, Yarker J, Haslam C, Ahmed S. Cognitive intervention for breast cancer patients undergoing adjuvant chemotherapy: a needs analysis. Cancer Nurs. 2011; 34(5): 385-92.
40. Todd BL, Feuerstein EL, Feuerstein M. When breast cancer survivors report cognitive problems at work. Int J Psychiatry Med. 2011; 42(3): 279-94.
41. Gijsen CP, Dijkstra JB, van Boxtel MP. Recurrent pain is associated with decreased selective attention in a population-based sample. Pain. 2011; 152(1): 188-93.
42. Wefel JS, Schagen SB. Chemotherapy-related cognitive dysfunction. Curr Neurol Neurosci Rep. 2012; 12(3): 267-75.
43. Dragun AE, Huang B, Gupta S, Crew JB, Tucker TC. One decade later: trends and disparities in the application of post-mastectomy radiotherapy since the release of the American Society of Clinical Oncology clinical practice guidelines. Int J Radiat Oncol Biol Phys. 2012; 83(5): e591-6.
44. Brewer GA, Ball BH, Knight JB, Dewitt MR, Marsh RL. Divided attention interferes with fulfilling activity-based intentions. Acta Psychol. 2011; 138(1): 100-5.
45. Fardell JE, Vardy J, Johnston IN, Winocur G. Chemotherapy and cognitive impairment: treatment options. Clin Pharmacol Ther. 2011; 90(3): 366-76.
46. Ferguson RJ, Ahles TA, Saykin AJ, McDonald BC, Furstenberg CT, Cole BF, et al. Cognitive-behavioral management of chemotherapy-related cognitive change. Psychooncology. 2007; 16(8): 772-7.
47. Kohli S, Fisher SG, Tra Y, Adams MJ, Mapstone ME, Wesnes KA, et al. The effect of modafinil on cognitive function in breast cancer survivors. Cancer. 2009; 115(12): 2605-16.
48. Warner ET, Tamimi RM, Hughes ME, Ottesen RA, Wong YN, Edge SB, et al. Time to diagnosis and breast cancer stage by race/ethnicity. Breast Cancer Res Treat. 2012; 136(3): 813-21.
49. de Winter JCF, Dodou D, Wieringa PA. Exploratory factor analysis with small sample sizes. Multivar Behav Res. 2009; 44: 147-81.
50. Feuerstein M, Todd BL, Moskowitz MC, Bruns GL, Stoler MR, Nassif T, et al. Work in cancer survivors: a model for practice and research. J Cancer Surviv. 2010; 4(4): 415-37.